[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337739-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337739-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-profiling-of-cancer-neoantigens-from-aberrant-rna-splicing","Comprehensive profiling of cancer neoantigens from aberrant RNA splicing","","Cancer neoantigens emerge from protein-altering somatic events and represent a leading class of next-generation immuno-oncology targets, especially when combined with immune checkpoint inhibitors. The study introduces SPLICE-neo, a computational module that identifies neoantigens from aberrant RNA transcripts originating from DNA splice-site mutations and de novo RNA splicing. Profiling across TCGA tumors, ranking by isoform expression and z-scores, and translating top isoforms into protein neoepitopes enable HLA binding validation via in vitro assays.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-profiling-of-cancer-neoantigens-from-aberrant-rna-splicing/337739/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-profiling-of-cancer-neoantigens-from-aberrant-rna-splicing/337739.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does SPLICE-neo address in neoantigen research?","Question",{"text":63,"@type":64},"It addresses the challenge of detecting neoantigens created by aberrant RNA splicing, including cases both with and without DNA splice-site mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does SPLICE-neo identify splicing-derived neoantigens?",{"text":68,"@type":64},"It profiles DNA splice-site mutations in TCGA tumors, computes transcript isoforms from frequent splicing gain/loss profiles, then detects de novo RNA aberrant splicing using RNA-seq reads mapped to novel exon junctions, ranks isoforms, and evaluates neoepitopes via REAL-neo.",{"name":70,"@type":61,"acceptedAnswer":71},"What key findings were reported across representative cancers?",{"text":72,"@type":64},"The study identified abundant splicing neoantigens in BRCA, LUAD, LUSC, and LIHC, including candidates with potent tumor-antigen activity and stronger HLA binding than a influenza-virus positive control.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337739,1790194121,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Open access Original research  \n Comprehensive profiling of cancer  \nneoantigens from aberrant RNA splicing  \nDaniel P Wickland  ,1 Colton McNinch,2,3 Erik Jessen,3 Brian Necela,4 Barath Shreeder,4 Yi Lin,5 Keith L Knutson  ,4 Yan W Asmann1  \nTo cite: Wickland DP, McNinch C, Jessen E, et al. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing. Journal for ImmunoTherapy of Cancer 2024;12:e008988 . doi:10 . 1136/ jitc-2024-008988  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-008988](jitc-2024-008988)) .  \nDPW and CM contributed equally.  \nAccepted 29 April 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA 2National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA  \n3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA 4Department of Immunology, Mayo Clinic, Jacksonville, Florida, USA  \n5Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA  \nCorrespondence to  \nDrYan WAsmann;  \n[asmann.yan@mayo.edu](asmann.yan@mayo.edu)  \nABSTRACT  \nBackground Cancer neoantigens arise from proteinaltering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computational framework, REAL-neo, for identification, quality control, and prioritization of both class-I and class-II human leucocyte antigen (HLA)-presented neoantigens resulting from somatic single-nucleotide mutations, small insertions and deletions, and gene fusions. In this study, we developed a new module, SPLICE-neo, to identify neoantigens from aberrant RNA transcripts from two distinct sources: (1) DNA mutations within splice sites and (2) de novo RNA aberrant splicings.  \nMethods First, SPLICE-neo was used to profile all DNA splice-site mutations in 11,892 tumors from The Cancer Genome Atlas (TCGA) and identified 11 profiles of splicing donor or acceptor site gains or losses. Transcript isoforms resulting from the top seven most frequent profiles were computed using novel logic models. Second, SPLICEneo identified de novo RNA splicing events using RNA sequencing reads mapped to novel exon junctions from either single, double, or multiple exon-skipping events. The aberrant transcripts from both sources were then ranked based on isoform expression levels and z-scores assuming that individual aberrant splicing events are rare. Finally, top-ranked novel isoforms were translated into protein, and the resulting neoepitopes were evaluated for neoantigen potential using REAL-neo. The top splicing neoantigen candidates binding to HLA-A*02:01 were validated using in vitro T2 binding assays.  \nResults We identified abundant splicing neoantigens in four representative TCGA cancers: BRCA, LUAD, LUSC, and LIHC. In addition to their substantial contribution toneoantigen load, several splicing neoantigens were potent tumor antigens with stronger bindings to HLA compared with the positive control of antigens from influenza virus. Conclusions SPLICE-neo is the first tool to comprehensively identify and prioritize splicing neoantigens from both DNA splice-site mutations and de novo RNA aberrant splicings. There are two major advances of SPLICE-neo. First, we developed novel logic models that assemble and prioritize full-length aberrant transcripts from DNA splice-site mutations. Second, SPLICE-neo can identify exon-skipping events involving more than two exons, which account for a quarter to onethird of all skipping events.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Tumor neoantigens can be leveraged to develop personalized,","cbCaiuppFS0t14Pz","https://ap.wps.com/l/cbCaiuppFS0t14Pz","pdf",4597784,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background (continued)","[{\"question\":\"What problem does SPLICE-neo address in neoantigen research?\",\"answer\":\"It addresses the challenge of detecting neoantigens created by aberrant RNA splicing, including cases both with and without DNA splice-site mutations.\"},{\"question\":\"How does SPLICE-neo identify splicing-derived neoantigens?\",\"answer\":\"It profiles DNA splice-site mutations in TCGA tumors, computes transcript isoforms from frequent splicing gain/loss profiles, then detects de novo RNA aberrant splicing using RNA-seq reads mapped to novel exon junctions, ranks isoforms, and evaluates neoepitopes via REAL-neo.\"},{\"question\":\"What key findings were reported across representative cancers?\",\"answer\":\"The study identified abundant splicing neoantigens in BRCA, LUAD, LUSC, and LIHC, including candidates with potent tumor-antigen activity and stronger HLA binding than a influenza-virus positive control.\"}]","Comprehensive profiling of cancer neoantigens from aberrant RNA splicing | PDF",1790020429,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/960481472811569f805e35267b7ecaf4.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdb31e9c98b95f4275632fa6a70c818c.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64699eb68186ebfeb579c3e9f04bed7a.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/055a8d59a0e63bade89afbd3520e129c.webp",980,1306]